Once again the market experienced late day volatility, but instead of a sell-off this time in the last hour of trading buyers pushed stocks to session highs.
Stocks fell sharply after a late selloff Monday after a report showed consumer credit rose slightly. Industrials, financials and tech were the weakest links.
Sales of a vaccine for late-stage prostate cancer, Dendreon’s Provenge, are expected to reach $1 billion in the first two years, analysts have predicted. This drug, one of several being showcased at the American Society of Clinical Oncologists meeting, represent a trend in which drugs treat a subgroup of cancer sufferers within the larger disease.
The euro fell below $1.19 for the first time in more than four years on Monday but recovered most of its losses as U.S. stocks rose slightly and strong German manufacturing data pushed investors to buy back the currency. Ashraf Laidi, chief market strategist at CMC Markets discussed his insights.
Stocks see-sawed Monday as investors were encouraged by strong German factory data but the market remained jittery.
We're especially excited about a potential new medicine called crizotinib. It's in late-stage studies to test whether it can help people living with a certain type of lung cancer, and whether it's safe for them to use it.
Stocks remained lower after a report showed fewer jobs were added to nonfarm payrolls than expected last month. How should investors position themselves? Roy Williams, CEO of Prestige Wealth Management, and Michael Sansoterra, co-manager of RidgeWorth Large Cap Growth Stock Fund, discussed their outlooks.
The latest overall job loss numbers showed a gain of 431,000 jobs in May and an unemployment rate falling to 9.7% from 9.9% in April. Here is a breakdown of where the job losses were as well as which sectors were adding jobs.
Sellers dominated May with the Dow's total monthly loss totaling 8%; that's the worst May drop since 1940. Are we in for a cruel summer?
Thanks Fitch. The ratings agency's latest downgrade could force the market to again test key levels of resistance. What must you know?
They are the highly trained, generally well-paid employees in the vanguard of American innovation: people who work in biotechnology labs. But the cutting edge can be a risky place to work.
It was a nasty morning on Wall Street but by afternoon gray skies turned to blue and the S&P inched its way into positive territory. What's going on?
Stocks wobbled in mid-afternoon trading Monday following a short-lived rally. How should investors position their portfolios? Mary Jane Matts, director of Fifth Third Asset Management, and David Spika, VP and investment strategist at WHG Funds, discussed their insights.
The week's vicious stock market slump set up the perfect buying opportunity for investors, who finally received their long-awaited market correction.
Nearly every large-cap U.S. company has some form of exposure to Europe and some are significantly more at risk than others. So which ones are the most affected and by how much? Roberto Pedone, contributor at TheStreet.com shared his insights.
Cramer makes the call on viewers' favorite stocks.
Billionaire investor George Soros, chairman of Soros Fund Management, detailed his fund's actions in the first quarter of the year in an SEC filing on Monday.
Does weakness in Europe signal the beginning of a global bear market or is it a fear-driven buying opportunity?
Pfizer, the world’s largest pharmaceutical company, plans to lay off or relocate up to 1,400 New York City employees, seven years after receiving millions of dollars in tax breaks to create jobs in the city. The New York Times reports.
With a perfect storm of chaos hitting the markets this week—protests in Greece, a possible Greek debt default and a near-1,000 point selloff in the Dow Jones Industrial Average—how can jittery investors find the confidence to enter the market?